Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15374693 | 1.00 | GPR84 (0.63) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14830349 | 0.85 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14831024 | 0.85 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14830350 | 0.85 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14830348 | 0.85 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| Pivalate SCHEMBL27707565 | 0.80 | FFAR1 (0.66) | GPR84FFAR1FFAR4NFKB1ACACB | |
| SCHEMBL5194248 | 0.79 | GPR84 (0.43) | GPR84FFAR1FFAR4CA2FAAH | |
| SCHEMBL5194244 | 0.79 | GPR84 (0.43) | GPR84FFAR1FFAR4CA2FAAH | |
| SCHEMBL5194151 | 0.79 | MAPT (0.48) | GPR84FFAR1CA2FAAH | |
| SCHEMBL5197793 | 0.79 | GPR84 (0.43) | GPR84FFAR1FFAR4CA2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372442-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor(\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230277621-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11744874-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230270819-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor (\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11679141-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220193187-A1 | Formulated and/or co-furmulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20210187066-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744874-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR4, TLR7 | GPR84 122/4885FFAR1 13/4885FFAR4 20/4885 |
| US-20230372442-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor(\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | TLR1, TLR7, TLR4 | GPR84 106/4885FFAR1 13/4885FFAR4 20/4885 |
| US-20220193187-A1 | Formulated and/or co-furmulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR9, TLR4 | GPR84 121/4885FFAR1 10/4885FFAR4 13/4885 |
| US-20230270819-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor (\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | TLR1, TLR7, TLR4 | GPR84 108/4885FFAR1 13/4885FFAR4 21/4885 |
| US-11679141-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR4, TLR7 | GPR84 122/4885FFAR1 13/4885FFAR4 20/4885 |
| US-20230277621-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR7, TLR4 | GPR84 106/4885FFAR1 13/4885FFAR4 20/4885 |
| US-20210187066-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR7, TLR4 | GPR84 106/4885FFAR1 13/4885FFAR4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.